Podcasts about Barda

Dev Mittar, Ph.D., Scientific Director of the ASM Health Scientific Unit discusses the use of metagenomic next generation sequencing to develop agnostic diagnostic technology, giving scientists and clinicians alike, a tool to diagnose any infectious disease with one single test. He also discusses how the ASM Health Unit is empowering scientists and leveraging microbial science innovations to address critical global health challenges and improve lives worldwide. Ashley's Biggest Takeaways The Division of Research, Innovation and Ventures is a small entrepreneurial arm of BARDA that takes on early-stage projects with high potential of turning into medical countermeasures. Prior to his role as Scientific Director for ASM Health, Mittar worked as a health scientist and program officer at DRIVe, where he focused on advancing high-impact science. He is particularly passionate about his work to develop agnostic diagnostics—a single test that uses metagenomic next generation sequencing to identify any pathogen from 1 clinical sample. Mittar discusses applications for this technology in surveillance (pandemic preparedness), variant detection, AMR and clinical settings (diagnosing complicated infections where etiology is not clearly defined). He also shares how a recent bout with illness emphasized the value and potential of this technology to save money, time, pain and suffering of the patient. Agnostic diagnostics can also help prevent the overuse/misuse of antibiotics, which are key factors in the spread of antimicrobial resistance. Furthermore, when this technology is coupled with the use of metatranscriptomics, it can provide information about the patient's immune profile that can be helpful in developing personalized treatment strategies, as opposed to a one-size-fits-all approach. ASM is organizing around 3 scientific units, ASM Health, ASM Mechanism Discovery and ASM Applied and Environmental Microbiology. These units will empower researchers and scientists to use science make a difference in the world and provide a forum for them to come together to shape the future of the field. Links for This Episode Learn More About ASM's Scientific Units. Join the Conversation on ASM Connect, our online community platform. Browse Volunteer Opportunities. Become an ASM Member. Register for ASM Microbe 2025.

00:04:20 - 00:14:25: FBI's Role in January 6 and Lack of TransparencyKash Patel and Dan Bongino's evasive responses on FBI's involvement in January 6, suggesting a deep state operation. Critique of their alignment with the party line, lack of clarity, and distrust in forthcoming information being filtered through Congress. Mentions Jeffrey Epstein's death as a non-suicide, reflecting broader skepticism of official narratives.00:31:50 - 00:42:13: Media Manipulation and PropagandaDiscussion of Caitlin Johnstone's article on how Western media uses distortions, emphasis, and omissions to shape narratives, particularly on Israel-Palestine. Emphasis on the need to focus on raw data to counter manipulation, with examples of underreported issues like starvation in Gaza versus overreported stories like Russia-Ukraine.00:46:29 - 00:59:40: Lab-Grown Meat as a Control MechanismCritique of lab-grown meat as a tool for corporate control, removing self-sufficiency in food production. Discussion of its ethical and environmental claims as hollow, with concerns about engineered scarcity and dependence on conglomerates. Mentions the unappetizing nature of lab-grown products like the “world's largest cultivated chicken nugget.”01:13:29 - 01:17:16: Montana's Ban on Warrantless Data PurchasesMontana's Senate Bill 282 prohibits law enforcement from buying personal data (e.g., geolocation, financial records) without a warrant, closing the data broker loophole. Critique of government's data buying/selling practices, with DMVs profiting millions (e.g., Florida: $77M, California: $52M in 2017).01:19:55 - 01:26:01: Meta's Facial Recognition Glasses and Surveillance RisksMeta plans to integrate facial recognition into Ray-Ban smart glasses, enabling real-time identification of passersby, raising severe privacy concerns. Unlike fixed cameras, mobile glasses are harder to detect, potentially enabling mass surveillance by individuals or government.01:27:35 - 01:37:47: Transphobia Investigation Over Lucy SkeletonBrazilian woman faces up to three years in prison for calling Lucy the skeleton female, deemed transphobic by activists who argue ancient fossils could have had modern gender identities. Critique of this as an attack on objective reality and scientific fact.01:55:04 - 02:00:25: Israel's Ethnic Cleansing and Occupation of GazaNetanyahu admits to ethnic cleansing goals in Gaza, citing destruction of homes and lack of countries accepting Palestinian refugees. Israel's blockade and use of food to lure starving civilians criticized as inhumane, with growing disapproval even among Republicans (Pew: 37% unfavorable views by 2025).02:00:42 - 02:12:27: Measles Panic and Vaccine DangersMedia exaggerates measles as the “world's most infectious disease” (e.g., one DC case, 300 in Texas out of 31 million). Child's death misattributed to measles was due to medical error (delayed antibiotics for pneumonia). Critique of vaccine schedules causing autism/allergies and mercury (thimerosal) in vaccines, requiring hazmat cleanup but injected into children.02:17:42 - 02:34:50: Susan Monterey's CDC Appointment and Biosecurity ConcernsSusan Monterey, appointed CDC director, criticized for biosecurity ties (ARPA-H, BARDA, DARPA) and vaccine advocacy. RFK Jr.'s endorsement as a Maha supporter questioned as a betrayal, given her support for AI-driven health projects (e.g., predicting diseases from personal data) and high-risk biomedical research, likened to pandemic manufacturing.02:34:50 - 02:42:09: NGOs and Government Funding Woke IdeologyUS government (CIA, USAID) and NGOs (Ford, Rockefeller Foundations) funded gay pride and transgenderism since the 1980s, evolving into woke ideology. Framed as a satanic agenda to destroy Western civilization, driven by spiritual forces beyond earthly institutions, with government as a tool of higher powers.02:47:22 - 03:03:14: Biological Computers and Brain-Computer InterfacesCortical Labs' Cow One uses human brain cells for neural networks, trained to play Pong, with potential for drug testing. DARPA, NIH, and Obama's BRAIN Initiative fund BCIs for military applications (e.g., memory transfer, neuro-weapons), raising concerns about mind control, transhumanism, and technocratic control via public-private partnerships.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

00:04:20 - 00:14:25: FBI's Role in January 6 and Lack of TransparencyKash Patel and Dan Bongino's evasive responses on FBI's involvement in January 6, suggesting a deep state operation. Critique of their alignment with the party line, lack of clarity, and distrust in forthcoming information being filtered through Congress. Mentions Jeffrey Epstein's death as a non-suicide, reflecting broader skepticism of official narratives.00:31:50 - 00:42:13: Media Manipulation and PropagandaDiscussion of Caitlin Johnstone's article on how Western media uses distortions, emphasis, and omissions to shape narratives, particularly on Israel-Palestine. Emphasis on the need to focus on raw data to counter manipulation, with examples of underreported issues like starvation in Gaza versus overreported stories like Russia-Ukraine.00:46:29 - 00:59:40: Lab-Grown Meat as a Control MechanismCritique of lab-grown meat as a tool for corporate control, removing self-sufficiency in food production. Discussion of its ethical and environmental claims as hollow, with concerns about engineered scarcity and dependence on conglomerates. Mentions the unappetizing nature of lab-grown products like the “world's largest cultivated chicken nugget.”01:13:29 - 01:17:16: Montana's Ban on Warrantless Data PurchasesMontana's Senate Bill 282 prohibits law enforcement from buying personal data (e.g., geolocation, financial records) without a warrant, closing the data broker loophole. Critique of government's data buying/selling practices, with DMVs profiting millions (e.g., Florida: $77M, California: $52M in 2017).01:19:55 - 01:26:01: Meta's Facial Recognition Glasses and Surveillance RisksMeta plans to integrate facial recognition into Ray-Ban smart glasses, enabling real-time identification of passersby, raising severe privacy concerns. Unlike fixed cameras, mobile glasses are harder to detect, potentially enabling mass surveillance by individuals or government.01:27:35 - 01:37:47: Transphobia Investigation Over Lucy SkeletonBrazilian woman faces up to three years in prison for calling Lucy the skeleton female, deemed transphobic by activists who argue ancient fossils could have had modern gender identities. Critique of this as an attack on objective reality and scientific fact.01:55:04 - 02:00:25: Israel's Ethnic Cleansing and Occupation of GazaNetanyahu admits to ethnic cleansing goals in Gaza, citing destruction of homes and lack of countries accepting Palestinian refugees. Israel's blockade and use of food to lure starving civilians criticized as inhumane, with growing disapproval even among Republicans (Pew: 37% unfavorable views by 2025).02:00:42 - 02:12:27: Measles Panic and Vaccine DangersMedia exaggerates measles as the “world's most infectious disease” (e.g., one DC case, 300 in Texas out of 31 million). Child's death misattributed to measles was due to medical error (delayed antibiotics for pneumonia). Critique of vaccine schedules causing autism/allergies and mercury (thimerosal) in vaccines, requiring hazmat cleanup but injected into children.02:17:42 - 02:34:50: Susan Monterey's CDC Appointment and Biosecurity ConcernsSusan Monterey, appointed CDC director, criticized for biosecurity ties (ARPA-H, BARDA, DARPA) and vaccine advocacy. RFK Jr.'s endorsement as a Maha supporter questioned as a betrayal, given her support for AI-driven health projects (e.g., predicting diseases from personal data) and high-risk biomedical research, likened to pandemic manufacturing.02:34:50 - 02:42:09: NGOs and Government Funding Woke IdeologyUS government (CIA, USAID) and NGOs (Ford, Rockefeller Foundations) funded gay pride and transgenderism since the 1980s, evolving into woke ideology. Framed as a satanic agenda to destroy Western civilization, driven by spiritual forces beyond earthly institutions, with government as a tool of higher powers.02:47:22 - 03:03:14: Biological Computers and Brain-Computer InterfacesCortical Labs' Cow One uses human brain cells for neural networks, trained to play Pong, with potential for drug testing. DARPA, NIH, and Obama's BRAIN Initiative fund BCIs for military applications (e.g., memory transfer, neuro-weapons), raising concerns about mind control, transhumanism, and technocratic control via public-private partnerships.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Feathers & Foes are back!  Let us know what you thought abbout issue 20 at feathersandfoes@gmail.com www.thehuntresspodcast.com www.patreon.com/wrightonnetwork BlueSky: Huestone44.bsky.social & mtnflwr1.bsky.social Birds of Prey: Issue 20       Released: April 2, 2025  Writer: Kelly Thompson      Art: Sami Basri with Vicente Cifuentes    Colors: Adriano Lucas   Lettering: Clayton Cowles    Editor: Jessica Berbey     Group Editor: Rob Levin Title: On the Run Part 1 In Gotham, Batgirl Cassandra Cain is investigating an apartment crime scene littered with clues. She bumps into Batman who agrees the crime scene belongs to the Birds of Prey. Back at the Birds' Headquarters, Oracle attempts to go through all the evidence. The group knows this is all a trap of some sort but there needs to be several in person investigations to solve what has happened and how it relates to a stolen experimental drug. They split up. That night in Gotham, Sin and Batgirl are on a stakeout. Sin is excited and apologizes for being a lot to put up with. Batgirl reassures her. They are a lot alike, trained to be weapons, bad people always want them. However they both are different inside and it's good. Sin gives her a hug. Meanwhile, Barda drops off Dinah in Tokyo. She makes her way down from the roof into a large theater where a demonstration of a new invisibility suit is underway. Dinah is shocked at how effective it is, Oracle calls it an industry game changer. Barda has boom tubed into United Arab Emirates and a small town that appears deserted. She investigates a strange nearby skyscraper. Although it has power, it too is empty. After getting into the penthouse she hears someone from the air ducts call out to her.  Back in Gotham, Sin and Bargirl are curious when their target leaves a club only to descend into the sewers. They carefully follow.  Barda reaches up to the grate of the air duct when tendrils of black slice down upon her. She drops her Megarod. The inky creature quickly heads for it. The room tilts as an alarm sounds. Barda's Megarod falls out the window with the ink creature. It grabs it and turns into a woman with glider wings. Barda is too busy to notice as the entire penthouse is launched into space. Oracle is trying to get feedback from Black Canary as Barda's intermittent communicator signal comes through. Oracle tells Barda all the Birds are under attack. Barda says she's in space, right before she discovers a bomb's onboard. It goes off with a huge boom and the ship explodes. Oracle frantically announces: “All Teams. This is a code black. Barda is down. I repeat, code black. Barda is down”.   Elsewhere a shadowy figures looks at pictures of the Birds saying “one down, four to go.”  

durée : 00:00:57 - Le musicien folk toulousain "Le Barda" - Country, folk, blues, Le Barda est un touche-à-tout de génie ! Découvrez aujourd'hui sur La Scène Toulousaine un grand musicien...

Feathers and Foes are back to talk about the Kelly Thompson banger! Write to us at feathersandfoes@gmail.com or www.patreon.com/wrightonnetwork Bluesky: huestone44.bsky.social Birds of Prey: Issue 19        Released: March 5, 2025  Writer: Kelly Thompson      Art: Juann Cabal      Colors: Adriano Lucas   Lettering: Clayton Cowles    Editor: Jessica Berbey     Group Editor: Rob Levin Title: Divide and Conquer Part 2 At the Lake House, Dinah and Sin's trap has succeeded and their stalkers attack. A huge fight ensues with Oracle supplying help via drones. But when Dinah moves in front of the window, she's hit by a sniper's bullet. Meanwhile in the magical streets of The Seam, Big Barda continues her battle with the golems. She smashes them only for them to reform. No problem. She opens a boom tube to the moon and hits or tosses them through. She grabs their controller, Barter, and threatens to do the same to him unless he tells her how many others are after Batgirl and Constantine. Elsewhere in The Seam, the demon controlled Constantine continues it's attempt to get Batgirl to free it from it's bonds. Needless to say she's not even tempted. When the final golems attack, Batgirl smashes them then separates the parts by tossing them in various stores and barrels along the road.  Back at the Lake House, Sin loses it when Dinah is shot at goes full Megaera, with green light blasting out of her and tendrils all doing their thing. She, or is it they, float out of the roof and threaten the League of Shadows, or whatever splinter cell this is, that they better gather their fallen and leave or she will take them apart. She further threatens to end them if she ever sees them again. Afterward Sin returns to care for Dinah. Dinah is worried if the being who just threatened the attackers was Sin or all Megaera. Sin isn't sure and Dinah reassures her they will find someone who can help. Back in The Seam, Batgirl and the demon infested Constantine reach the portal where the demon must be deposited. She rebuffs it again and is about to toss it in when Barda arrives to kick it through. A few moments later, the freed Constantine returns to the street. Dinah and Sin settle down to watch the sun rise at the Lake House. Sin expresses another concern. Some of the League of Shadows assassins she threatened appeared to be happy. She's possibly given them something new to covet: Megaera.   

Amerikalıların günde 330 milyona kadar plastik pipet kullandığı tahmin ediliyor - şimdi Başkan Trump bunları aşamalı olarak kaldırma çabalarını tersine çevirdi. Peki çevresel etkiler neler ve Avustralya plastik pipetleri yasaklama konusunda hangi aşamada?

Send us a textProf. Dr. Niels Riedemann, MD, Ph.D. is Chief Executive Officer and Founder of InflaRx ( https://www.inflarx.de/Home/About-Inflarx/Team~Niels-C.-Riedemann~.html ), a biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR inhibitors to the treatment of life-threatening or debilitating inflammatory diseases with high unmet medical need. Prof. Dr. Riedemann has over 15 years of experience in the biotech industry and drug development, as well as over 20 years of experience in complement immunology research. He founded InflaRx in 2007 and has served as Chief Executive Officer since inception of the company. He has been instrumental in and led numerous private and public financing rounds of the company and has been the responsible lead for its Nasdaq IPO in 2017. He is named inventor on several internationally granted core patents of InflaRx. As physician, Prof. Dr. Riedemann was appointed Vice Director (“Leitender Oberarzt”) of Intensive Care Medicine, and led a 50-bed University ICU unit for over 6 years at Friedrich Schiller University, Jena, Germany until 2015. Before that, he received his board certification as General Surgeon upon completion of his surgical fellowship at MHH (Hannover Medical School, Germany) in 2007 where he also received his habilitation (equivalent to Ph.D.) and where he still holds an Adjunct Professorship (APL Professor). He spent three years as postdoctoral research fellow at the University of Michigan, USA until 2003. He received his medical training at Albert Ludwig University (ALU), Freiburg, Germany, and Stanford University, USA and graduated as Dr. med. (equivalent to M.D.) from ALU in 1998. Prof. Dr. Riedemann's research has been awarded with several national and international awards. He has received extensive extra-mural funding and published over 60 peer reviewed scientific publications in highly ranked journals. He has served as a member on a Board of Directors and a Scientific Advisory Board of two large scientific governmental funded programs. He currently serves as Co-Chair of the Health Politics working group of Bio-Deutschland and he serves as member of the board of trustees for the German Sepsis Foundation.#NielsRiedemann #InflaRx #Inflammation #ComplementComponent5a  #Sepsis #AcuteRespiratoryDistressSyndrome #Covid #ARDS #GOHIBIC #Vilobelimab #PyodermaGangrenosum #ChronicSpontaneousUrticaria #HidradenitisSuppurativa #Preparedness #BARDA #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Sürekli başkalarına yetişmeye çalışırken kendini ihmal ettiğini fark ettin mi? Peki, sen tükenmişken başkalarına nasıl destek olabilirsin? Bu bölümde, kendimizi ihmal etmeden dengeli ve tatmin edici bir hayat yaşamanın yollarını konuşuyoruz.

David Druid och Linnea Wikblad är marginalfria, Cassandra Klatzkow fryser sina ägg och Cecilia Uddén om vapenvilans första dag. Lyssna på alla avsnitt i Sveriges Radio Play. Hela veckans Morgonpasset i P3 hör du i Sveriges Radio Play.Vi kan inte få nog av Jean-Pierre Barda som lär oss allt om Village People! Cassandra Klatzkow från podden ”Det skaver” fryser sina ägg och berättar om processen! Mellanösternkorren Cecilia Uddén på plats i Jerusalem om vapenvilans första dag. David Druid och Linnea Wikblad tillhör minoritetsgruppen ”marginalfria”. Linnea förstör avokadon för miljöns skull – clean ween! Matilda Rånge på P3 Nyheter om vapenvilan och att Trump svärs in. Matilda Rånges obekväma falska lilla hål: Router.Tidpunkter i avsnittet:18:06 Nyhetsfördjupning: Vapenvilan i Gaza.23:29 Jean-Pierre Barda om Village People och YMCA.46:37 Nyhetsfördjupning: Trump svärs in.57:33 Matilda Rånges obekväma falska lilla hål: Router.1:02:52 Cecilia Uddén i Jerusalem.1:18:09 Cassandra Klatzkow.Kapitellänkarna ovan leder till avsnittet utan musik i Sveriges Radio Play.Programledare: David Druid och Linnea Wikblad.

Antonín Kotík vykládal příjmení Velda z adjektiva velký. Patřilo by tak mezi pojmenování podle vlastností. Podle Josefa Beneše je však třeba vykládat příjmení Velda spíše z rodného jména s příponou -da, analogicky k příjmením jako Karda z Karel, Šalda z Šalamoun, Barda z Bartoloměj apod. Základem příjmení Velda bylo nejspíše rodné jméno Veleslav, Velimír apod. V současnosti u nás nosí příjmení Velda/Veldová 25 obyvatel.Všechny díly podcastu O původu příjmení můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

This week Dr. Evan Loh, Paratek CEO, returns to Off theShelf to share the latest in the biopharmaceutical company's partnership withthe Biomedical Advanced Research and Development Authority's (BARDA's) Project BioShield. Paratek's antibiotic, NUZYRA (omadacycline) has beendesignated “an essential” medicine by the FDA, and Loh provides an updateon the progress made in onshoring of manufacturing of NUZYRA, from theproduction of API through finished drug product for both IV and oralformulations. Loh shares the journey to domestic manufacturing, highlighting the critical role Paratek's public-private partnership with BARDA played in developing manufacturing capability.Antimicrobial resistance (AMR) along with biological threat actors are continuing and growing threat and Loh discusses the current environment and the key policy considerations incombatting these and other healthcare threats. Finally, Loh talks about the potential that the results from the successful development of treatments through public-partnerships have the potential to be leveraged to support/protectthe warfighter.     Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week Dr. Evan Loh, Paratek CEO, returns to Off the Shelf to share the latest in the biopharmaceutical company's partnership with the Biomedical Advanced Research and Development Authority's (BARDA's)  Project BioShield.  Paratek's antibiotic, NUZYRA (omadacycline) has been designated “an essential” medicine by the FDA, and Loh provides an update on the progress made in onshoring of manufacturing of NUZYRA, from the production of API through finished drug product for both IV and oral formulations.  Loh shares the journey to domestic manufacturing, highlighting the critical role Paratek's public-private partnership with BARDA played in developing manufacturing capability. Antimicrobial resistance (AMR) along with biological threat actors are continuing and growing threat and Loh discusses the current environment and the key policy considerations in combatting these and other healthcare threats.  Finally, Loh talks about the potential that the results from the successful development of treatments through public-partnerships have the potential to be leveraged to support/protect the warfighter.     Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Prakash Narayan is a distinguished biotech executive with over 20 years of experience in leading IND- and BLA-enabling programs from concept through clinical trials for heart, lung, kidney, and liver indications. As a founding member of a startup biotech that became a publicly traded company, Dr. Narayan has demonstrated exceptional leadership skills and a proven track record in nonclinical and translational R&D, attracting approximately $30 million in non-dilutive funding as a Principal Investigator from various organizations including NIH, NSF, DoD, and BARDA 00:00 Introduction to the Life Science Success Podcast 00:37 Sponsor Message: D3 Digital Media Marketing 01:10 Guest Introduction: Dr. Prakash Narayan 01:51 Journey from Academia to Biotech Executive 04:34 Growing a Startup into a Publicly Traded Company 06:49 Drug Development Process: From Discovery to FDA Filings 12:53 Challenges and Future of Cell-Based Therapies 16:10 Predictive Analytics in Biomedical Science 19:10 Adapting Approaches Across Disease Areas 22:56 Precision Medicine in Clinical Trials 24:40 Understanding Fatty Liver Disease 25:00 Precision Medicine: A Tailored Approach 25:25 Repurposing Drugs for Kidney Disease 27:10 The Role of Biobanks and Electronic Health Records 28:26 Non-Dilutive Funding: Pros and Cons 32:56 Exploring Transcriptomics and Functionomics 36:55 The Impact of Technology and AI in Medicine 40:53 Inspiration and Concerns for the Future 47:42 Final Thoughts and Advice for Entrepreneurs  

Bardağa dökülen umut gibi her yudumda başka bir hikaye… Kimi için sabahın sessiz yoldaşı, kimi için bir damla yağmurun hatırası… Sadece bir kültür olmanın ötesinde köy meydanında da şehrin en popüler caddesinde de hayatın kendisidir çay. Marketing Türkiye için XSIGHTS'ın gerçekleştirdiği araştırma “bir bardak çayda saklı hayat aslında” cümlesini kurduruyor insana. Araştırma sonuçlarına göre Türk halkının %92'si her gün çay içiyor ve büyük çoğunluğu 5 bardak ve üzerinde kalplerini birleştiriyor ince belli camda. Peki, neden bu kadar çok çay tüketiyoruz? Bu sorunun cevabı, toplumun ekonomik ve sosyal dinamiklerinde saklı.

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) CEO Doug Ward takes Proactive's Stephen Gunnion through the company's achievements in 2024 and plans for the year ahead. Ward highlighted several key milestones, including the signing of a strategic partnership with Hologic and progress with its flagship products, ViraDx and FebriDx. He emphasised that FebriDx is transforming treatment by differentiating between bacterial and viral infections, helping to combat antibiotic resistance. Ward also discussed Lumos's collaboration with the Biomedical Advanced Research and Development Authority (BARDA), which funded a clinical trial to expand FebriDx's accessibility. He noted, “This is a huge win for Lumos, enabling us to go from 18,000 locations to 220,000 locations in the US with CLIA waivers.” Furthermore, the company successfully secured A$10.00 million in funding, attracting key investors like Tenmile and Ryder Capital. Ward expressed optimism for 2025, focusing on revenue growth, the BARDA-funded trial, and enhancing their partnerships. Visit Proactive's YouTube channel for more insightful interviews. Don't forget to like, subscribe, and enable notifications for future updates! #LumosDiagnostics #FebriDx #DiagnosticInnovation #AntibioticStewardship #HealthcareSolutions #HologicPartnership #BARDA #PointOfCareTesting #MedicalDevices InvestmentNews #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Join us on Friday Nights @ 7:00 PM EST on our Youtube channel  https://www.youtube.com/@WeirdScienceComics when we do the Absolute show LIVE!   YouTube: https://www.youtube.com/@WeirdScienceComics This Week's Patreon-Exclusive Spotlight Show is Two-Face #1 & Poison Ivy #28   Listen to the Spotlight Podcast by signing up to our Patreon - https://www.patreon.com/weirdscience   0:00:00 - Intro 0:17:18 - Action Comics #1078 0:49:59 - Batman #155  1:21:27 - JSA #2 1:43:17 - Shazam! #18 2:03:24 - Batgirl #2 2:13:06 - Birds of Prey #16   FOLLOW WEIRD SCIENCE COMICS Twitter:  https://twitter.com/WeirdScienceDC  Patreon: https://www.patreon.com/weirdscience DC Comics Review Site: https://bit.ly/WeirdScienceDC Marvel Review Site: https://bit.ly/WeirdScienceMarvel   SUBSCRIBE TO WEIRD SCIENCE COMIC PODCASTS:  DC Comics Podcast iTunes - https://apple.co/47jNeme Spotify - https://spoti.fi/2XzDALI Stitcher - https://bit.ly/45XPtKS  

Birds of Prey: Issue 16 Released: December 4, 2024 Writer: Kelly Thompson Art: Sami Basri Inker: Vicente Cifuentes Colors: Adriano Lucas Lettering: Clayton Cowles Editor: Jessica Berbey Group Editor: Rob Levin Title: Bird Undercover Part 3 Cassandra Cain's undercover mission into The Ninth Day Corporation has landed her in a secret sub-basement labyrinth facing Bella, a mutated woman who is now a dog like werewolf creature. However, after Cass uses a brick to break Bella's electronic collar, the beast becomes a friend. Cass uses Bella to trick her way into the guard's chamber. She takes some of the guard's equipment before climbing up the elevator cable and back into the ventilation ducts. She sees a woman about to be injected with a green substance and crashes into the room. She frees the woman who flees into the air duct. Cass now finds herself facing Xane, Jens, and Chet again. She sees that Xane is still wearing her secret communication bracelet. She uses a smoke grenade to distract him as she presses something to activate the bracelet. Except this has given one of the others time to hit her in the back with the syringe. Meanwhile at the Birds Headquarters, the other Birds have been anxiously awaiting word from Cass since she missed the last two check in times. Oracle is finally able to translate the message Cass send before her initial capture and the group sets out through one of Barda's boom tubes into the basement lab of the Ninth Day Corporation. As the scientists flee, gas is released and the Birds done their gas masks. They're then confronted by 4 grotesquely muscled mutated women. Black Canary, Big Barda, Onyx, and Grace take them out. However, as Black Canary uses a device to allow Oracle access into the computer she sees a sight that horrifies them: a grotesquely muscled mutated Cassandra Cain.    Write to us at feathersandfoes@gmail.com www.thehuntresspodcast.com Bluesky: @huestone44.bsky.social www.patreon.com/wrightonnetwork  

(00:00:00) The Geek Matrix Pod reviews DC's Weekly Comics Releases This week, (11/20/24), that's: (00:52:42) #Shazam 18 (01.02.07) #JSA 2 (01.12.35) #PoisonIvy 28 (01.23.50) #BirdsofPrey 16 (01.31.40) #TwoFace 1 (01:45:30) #ActionComics 1078 (01.54.50 ) #Batman 155 (02.15.25) #AbsoluteSuperman 2 (00:47:58) Plus our Honorable Mentions covered each week by Josh! Here's the run down – Variants Fico Ossio's variant for JSA #2 is like beautiful. David Nakayama's cover D for Action Comics 1078 is literally beautiful. Mateus Manhanini on Absolute Superman 2 is on fire and both JonBoy Meyers and Bjorn Barends draw covers I'd love to have. Titles DC's Batman Smells, Robin Laid an Egg #1 - John Stewart, The Secret Six, John Constantine, The Joker, Deadman, Dr. Mid-Nite, Vixen, and Superman get their own little crazy Holiday stories from DC's annual anthology book. And it's not bad. Typical seasonal anthology, if you can get past the cover. 7/10 DC Horror Presents: Creature Commandos #3 – This is dark, gritty, written well and a fun read. I hope that it continues because so far, we've got a really good main universe Horror book here, and I'd like to keep it that way. 8.25/10 Batman / Santa Claus: Silent Knight Returns #2 – It's amazing art, stellar, which a big cast of popular characters and a story that, so far, looks to out do our last go round with the Silent Knight. I'm all in for this series. Good time. 8/10 DC Horror Presents... #2 – Two twisted tales for The Penguin and Scarface. The Penguin one wasn't bad., The Scarface one was really good, if not a little messed up. Good stuff. 7.75/10 Little Batman Month One #2 – This continues to be a fun story for everyone, and suitable for the younger crowds. The comedy is just great. 8/10 Batgirl #2 – Continuing the story, Cass is forced to do things she doesn't want… like leave Gotham. But with this new enemy, is that the right choice? Second issue, and it's a killer. 8.25/10 Scooby-Doo, Where are you 131, Batman and Scooby Doo Mysteries #12 – Dash comes back next week. #Shazam #JSA #PoisonIvy #BirdsofPrey #TwoFace #ActionComics #Batman #AbsoluteSuperman #DCAllIn #AllIn #Absolute #DCComics #comics #comicbooks --- Support this podcast: https://podcasters.spotify.com/pod/show/thegeekmatrixcomics/support

Welcome, Bat-fans, to another fang-tastic episode of The BATTASS Podcast! Today, your hosts, Clay McCormack and Sean Murphy, are slithering into the world of Batman Beyond to cover two unforgettable episodes: *The Call* and *Curse of the Kobra*. But before we dive in, I need to get something off my chest—or maybe off my arm, because that's where yet another snake just sank its teeth into me! You'd think after years of handling snakes, I'd have figured out how to avoid getting bitten, but nope! It's like these slippery little suckers are out to get me. But hey, they say venom builds character, right?Anyway, back to Gotham! First up, *The Call* is an epic two-parter that introduces Terry McGinnis to the Justice League of the future. It's a jaw-dropping crossover featuring Superman, Barda, and more, with Terry stepping into the big leagues. Clay and Sean will dig deep into the intrigue, betrayal, and the weighty legacy of heroes old and new. And believe me, there's more venom in this story than even my snake pit at feeding time!Next, we've got *Curse of the Kobra*, where Terry faces off against a deadly martial arts cult led by the menacing Kobra. There's action, suspense, and plenty of reptilian vibes—though thankfully, no actual snake bites (unlike my day). Clay and Sean will unpack this pulse-pounding tale and the evolution of Terry as Batman as he goes toe-to-toe with some of his most formidable foes yet.So, while I'm busy nursing another bite wound and wondering if snake wrangling was really the right career choice, Clay and Sean are here to deliver sharp insights, compelling analysis, and, as always, a healthy dose of Bat-love. Grab your headphones and join The BATTASS Podcast for another hiss-terical and action-packed episode!

In this episode of BioTalk, Rich Bendis sits down with Rachel Rath, the Head of JLABS @ Washington, DC, to discuss her journey and insights on building a thriving ecosystem for life sciences innovation. Rachel shares her academic and professional background, from roles at PCORI and BARDA Blue Knight to leading JLABS @ Washington, DC. She offers an in-depth look at JLABS' national and international footprint, and the significant partnerships with organizations like Children's National, Virginia Tech, and BARDA that strengthen the innovation landscape across the mid-Atlantic.   Tune in as Rachel shares the current priorities at JLABS, highlighting the diversity of its tenant portfolio, which spans MedTech, Pharma, and Integrated Healthcare Solutions. She also discusses how JLABS companies benefit from the support and resources available through Johnson & Johnson, including access to valuable connections, mentorship, and funding opportunities via JJDC.   Located in the heart of the BioHealth Capital Region, JLABS @ Washington, DC is well-positioned to drive collaboration and ecosystem growth. Rachel sheds light on the unique advantages of this strategic location and shares her views on addressing the challenges faced by life science startups, from funding access to investment connectivity, and the vital steps needed to elevate the region's biohealth ecosystem.   Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).   Rachel is responsible for setting the strategic direction and overseeing all operational activities for JLABS @ Washington, DC. Her responsibilities include P&L management, external engagement, innovation sourcing, portfolio management, and operational excellence in collaboration with the team responsible for the site and the region. In addition to managing the business of JLABS, Rachel is responsible for the process of evaluating, selecting and accelerating a strong portfolio of innovators connected to JLABS @ Washington, DC, which supports companies across the broader region.   Prior to this role, Rachel served as the inaugural Director of the BARDA Alliance for Johnson & Johnson Innovation. As BARDA Alliance Director, she was responsible for managing BLUE KNIGHT™, a joint initiative between JLABS and the Biomedical Advanced Research and Development Authority (BARDA), which aims to stimulate the innovation and incubation of science and technologies. Rachel led the strategic direction, alliance management, and oversight of all operational activities related to BLUE KNIGHT™, including managing the sourcing and selection of high potential companies for JLABS locations and developing global programming including the annual BLUE KNIGHT™ Symposium.   Before joining JLABS, Rachel was the Chief of Staff for the National Evaluation System for health Technology Coordinating Center (NESTcc)—an initiative of the Medical Device Innovation Consortium (MDIC)—that was established with funding from the U.S. Food and Drug Administration (FDA) and was recognized in September 2019 as one of the first collaborative communities with participation by the FDA. Prior to joining NESTcc, Rachel worked at PCORI, helping to launch the Patient-Centered Clinical Research Network (PCORnet), a national effort to engage patients and leverage electronic health data to improve the speed and efficiency of clinical research in the United States.   Rachel received her MBA from Georgetown University and MPH in global health policy from The George Washington University.

Tune in for the latest news and trends in this month's episode of the Scope of Things, where host Deborah Borfitz covers everything you need to know about a pending launch of a large treatment trial for Graves' disease, a recruitment campaign for a diagnostic tampon, Walgreens and BARDA's new partnership, how eligibility criteria has been excluding people of African or Middle Eastern descent from cancer studies, and more. Joining the discussion is Aaron Mackey, vice president of AI and data science at Lokavant, who talks about the unintended consequences of decisions made during trial planning that can lead to questionable conclusions, how AI and ML are helping with the diversity issue in trial participation, and his stop gap emergency plan to keep trials on track if there is no digital support available. SHOW NOTES News Roundup Phase 3 trial for Graves' disease Article in Clinical Research News  Quality of life measures in cancer studies Study in Journal of Clinical Oncology Article in Clinical Research News Rapid recruitment for a diagnostic tampon trial Article in Clinical Research News Reference trial emulation Study in PLOS Medicine  Walgreens/BARDA partnership News brief in Clinical Research News “Detective” algorithm for improving trial design Study in Nature Genetics Exclusion of people with Duffy-null phenotype Study in JAMA Network Open    The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

En Oaxaca continúa la suspensión de clases en cinco regiones del estado El Poli te invita a participar en el concurso SexOlimpiadas PolitécnicasSanciona EU a dos empresas con sede en México propiedad de traficantes de fentanilo  Más detalles en nuestro Podcast

Is the world readying for Ezekiel 38-39?  Do NATO, the EU, and Russia all know that nuclear war is coming?  Why doesn't America know/isn't being warned?  Why are post vaxx statistics not being published in some Scandinavian countries any longer?  The WEF now admits that the Covid assault on society was all about testing our ____.  What does candidate Trump mean when he says, "If you elect me, Christians, you won't have to vote any more?"  Trump's assassins were previously both actors in a _____.  Israel is joining what war?  Please join Steve and Bonnie for a look into what could be our final weeks before ... our walking a path that will lead to ...  Yeshua ...  face-to-face. Plandemics There never was a Corona virus: https://www.globalresearch.ca/there-never-was-a-virus-there-never-was-a-pandemic/5841105 Post-vaxx death and illness stats so bad Norway won't publish: https://substack.com/@stevekirsch/p-148189713 A mountain of sites reporting vaxx injury/death: https://rootforamerica.com/covid-vaccine-dangerous-and-deadly/ Virologist - mpox in Covid vaxx: https://halturnerradioshow.com/index.php/news-selections/world-news/virologists-blow-the-whistle-mpox-is-actually-known-side-effect-of-covid-vax FDA concealed study of Mpox vaxx on 100,000 military personnel, concluded “safe and effective” because of trials of 24 monkeys instead: https://open.substack.com/pub/karenkingston/p/the-fda-authorized-and-then-concealed?r=12g59e&utm_campaign=post&utm_medium=email People are too smart for any more vaxxes so let's release genetically modified mosquitoes: https://open.substack.com/pub/2ndsmartestguyintheworld/p/psyop-eee-massachusetts-town-approves?r=12g59e&utm_medium=ios MUST DOWNLOAD!!! Pfizer doc 5.3.6, postmarketing experience, 1291 specific adverse reactions, intended to be unavailable for 75 years: https://childrenshealthdefense.org/wp-content/uploads/pfizer-doc-5.3.6-postmarketing-experience.pdf#page=30 List of studies showing C19 vaxx “worst healthcare disaster in world history”: https://rootforamerica.com/covid-vaccine-dangerous-and-deadly/ WEF admits – C19 a beta test to measure blind compliance: https://leohohmann.substack.com/p/world-economic-forum-finally-tells?r=qrouj&utm_medium=ios&triedRedirect=true Natural News – Covid was a beta test: https://www.naturalnews.com/2024-09-12-wef-admits-covid-test-obedience-globalism.html Nanobots capture living cells to build something new: https://t.me/GodsRoadmap/2148 Walgreen's new wealth – vaccine “research” on women/children with $100 mil contract from BARDA: https://open.substack.com/pub/sashalatypova/p/walgreens-pharmacy-chain-gets-100m?r=12g59e&utm_campaign=post&utm_medium=email Outpouring of Spirit needed because medical system as overwhelmingly failed us:  https://open.substack.com/pub/vigilantfox/p/horrific-vaccine-injury-leaves-23?r=12g59e&utm_campaign=post&utm_medium=email Experiments on children easier after new rule of Jan. '24: https://open.substack.com/pub/sashalatypova/p/the-fda-simplifies-experimentation?r=12g59e&utm_campaign=post&utm_medium=email Experts baffled at death rates in the young: https://fackel.substack.com/p/ive-never-seen-anything-like-this?utm_source=substack&utm_campaign=post_embed&utm_medium=web US navy crippled by adverse reactions of Covid vaxx: https://www.naturalnews.com/2024-08-28-navy-crippled-covid-vaccines-17-ships-sidelined.html Covid vaxx effect on economy: https://www.thetimes.com/uk/politics/article/sickness-benefits-mental-health-ct328xxjc Physician who quit at beginning of Covid looks back: https://thepeoplesvoice.tv/top-doctor-we-were-told-to-deliberately-kill-millions-of-covid-patients-using-ventilators/ NWO Plans Albert Pike's 3 World Wars: https://expose-news.com/2023/10/21/albert-pikes-plan-for-three-world-wars/ Albert Pike's 3rd WW in the making: https://medium.com/@newsonchain/albert-pike-three-world-wars-a-one-world-government-c7fefff7008a

Violencia en Sinaloa impide rescate de una tigresa No te pierdas el recorrido guiado por la  Sierra de Santa CatarinaServicio secreto de EU asume responsabilidad por el atentado contra Trump 

OPPOSITES ATTRACT NGA BA?Sino kaya kina Barbie Forteza at David Licauco ang “very demure, very cutesy and very mindful?” Totoo bang maraming nambabash kay Barbie na gumaganap bilang Adelina sa Kapuso family drama na “Pulang Araw” dahil hindi raw ito magaling umarte? Ano kaya ang say dito ni David aka Hiroshi? Forda BarDa fans out there — malalaman n'yo na lahat ‘yan sa bagong episode ng Updated with Nelson Canlas! Hosted on Acast. See acast.com/privacy for more information.

Bu bölümde yaşların hediyelerinden, yaşlanma kelimesini olgunlaşma ile değiştirmekten bahsediyoruz. Bardağın ne tarafından bakarsak artık... Keyifli dinlemeler

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Biopharma news on August 21, 2024 saw changes in Biomarin's C-suite, with Greg Friberg and James Sabry taking over R&D and business development. BridgeBio launched GondolaBio for rare disease drug programs, while Regeneron faced FDA setbacks for a myeloma drug. Avidity and Kymera raised funds, Walgreens partnered with Barda, and Merck licensed an antibody drug conjugate. Thermo Fisher Scientific supported oncology research with new developments in clinical trials. Overall, the industry saw leadership changes, setbacks in drug approvals, fundraising activities, partnerships, and innovations in clinical trials.A study suggested that patients on Novo Nordisk's semaglutide may have a higher risk of suicidal thoughts. The FDA denied Regeneron's drug approval for myeloma due to manufacturing issues. Lawmakers raised concerns about US biopharma companies working with the Chinese military. Novo Nordisk, Eli Lilly, and Sanofi are each focusing on different markets for their diabetes GLP-1 drugs. The impact of recent Supreme Court decisions on the healthcare and pharma industries is discussed, including challenges against regulations and reforms proposed by President Joe Biden. The uncertainty could jeopardize FDA authority and provisions in the Inflation Reduction Act, adding complexity for pharma companies.The Biosecure Act revealed gaps in domestic drug manufacturing readiness in the US. Different strategies of Novo Nordisk, Eli Lilly, and Sanofi in developing and distributing their GLP-1 drugs were highlighted. A gene therapy patent ruling raised intellectual property concerns, Genentech closed its cancer immunology group, and layoffs were reported in the industry. House lawmakers expressed worries about US biopharma companies collaborating with the Chinese military on trials. Aadi Bioscience plans to lay off 80% of its R&D staff.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.J&J has acquired heart failure implant maker V-Wave for up to $1.7 billion, while Medtronic reiterates its unchanged diabetes strategy despite a partnership with Abbott. Histosonics secured $102 million for a noninvasive tumor treatment using sound waves, and Edwards acquired Genesis' TAVR technology. The FDA approved NowDiagnostics' at-home syphilis test, offering results in 15 minutes with a drop of blood. The biotech industry remains strong in 2024, with startups thriving and technology advancements. Small biopharma and CROs are adopting multiple trial technologies, as per a recent survey.23andMe, known for consumer genetic testing, focuses on therapeutics development despite financial struggles and data breach lawsuits. Their lead candidate targets a new cancer treatment pathway using checkpoint inhibitors. Lilly's diabetes drug tirzepatide shows promise in reducing type 2 diabetes risk, while J&J's Rybrevant and Lazcluze combo is FDA-approved for lung cancer. Avidity and Kymera raised funds, Walgreens partnered with BARDA, and Merck licensed an antibody drug conjugate. Humana settles Medicare Part D fraud allegations, Steward hospitals in Massachusetts must sell five facilities, and McLaren Health Care faces another ransomware attack.Eli Lilly's tirzepatide demonstrates a 94% risk reduction for type 2 diabetes in overweight adults, and J&J's Rybrevant combo is the first chemo-free treatment for non-small cell lung cancer. Walgreens and BARDA collaborate to boost decentralized clinical trials, while three drugs are projected to drive drug price negotiation savings in 2026. Quality Assurance and Regulatory Affairs roles are crucial for market access, AbbVie and Genmab expand Tepkinly's European label, and biopharma companies like Lykos, Galera, and Grail announce staff reductions. AstraZeneca receives FDA approval for Imfinzi's perioperative use.Lykos restructures with significant staff cuts post-FDA rejection of their therapy, Acelyrin shifts focus to thyroid eye disease treatment after layoffs. Biotech IPO sizes are increasing despite slow IPO rates, Lilly opens an R&D hub in Boston, Ovid and Lexicon downsize staff. Stay informed with Biopharma Dive's comprehensive coverage of biotech and pharma industry news.

"The intersection of medicine, business and courageous creativity is where I've spent most of my career" Wendy Dean MD     In S5 E9 I am delighted to introduce another "heavy hitter" in healthcare thought leadership and transformational practice, Wendy Dean MD, president and co-founder of Moral Injury of Healthcare. Dr Dean is an alum of Smith College and the University of Massachusetts Medical School. She trained in surgery and psychiatry at Dartmouth Hitchcock Medical Center. After practicing for a decade, Wendy worked for the US Army, where she managed regenerative medicine research funding and guided strategy for a $70M investment in the emerging field of hand and face transplants. In that position, and as a senior executive at a large nonprofit in Washington, D.C., she worked closely with both the civilian and military medical communities, and many government agencies--BARDA, NIH, WHOSTP, NASA, DARPA--to develop novel strategies to restore form, function and appearance to ill and injured service members. She remains part of those communities as a board member and prize judge.          In describing her mission she says,"My focus now is on finding innovative ways to make medicine better for both patients and physicians through my own non-profit and by helping new talent and new ventures realize their big ideas."               Farming, fencing, photography, and riding big, opinionated horses keeps me focused outside of work.               In this conversation Wendy discusses the concept and definition of moral injury in medicine, how it is distinct but can co-exist with burnout, the implication of this for medical systems and organisations and the evolution of her own thinking and practice in this area since the publication of the OpEd she co-authored in 2018 "Clinicians aren't burning out they are suffering from moral injury". We discuss her book "If I Betray these Words" from idea to fruition and the challenges and opportunities of elevating clinical voices through story. The major part of this conversation is directed towards transformational leadership and practice in the modern day "business" of healthcare. Who is doing it well and what is working well? Wendy's commitment to mission and purpose and willingness to challenge her own and our collective thinking and practice permeates this entire episode. Thank you for energising me and for all the work that you do to move us forward towards a brighter future for healthcare. Links/References/Reading/Listening:https://wendydeanmd.comhttps://www.linkedin.com/in/wendy-dean-md/https://www.fixmoralinjury.org/what-is-moral-injuryhttps://www.penguinrandomhouse.com/books/718606/if-i-betray-these-words-by-wendy-dean-and-simon-talbot/ https://www.statnews.com/2018/07/26/physicians-not-burning-out-they-are-suffering-moral-injury/https://podcasts.apple.com/au/podcast/43cc/id1715895952 The Mind Full Medic Podcast is proudly sponsored by the MBA NSW-ACT Find out more about their service or donate today at www.mbansw.org.auDisclaimer: The content in this podcast is not intended to constitute or be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your doctor or other qualified health care professional. Moreover views expressed here are our own and do not necessarily reflect those of our employers or other official organisations.

El Camino de los Faros o “Camiño dos Faros” es la ruta más moderna y no oficial de los diferentes Caminos de Santiago. Quizá por eso sea tan desconocida, pero es un camino que bordea la Costa da Morte con una longitud de 200 km pegados al mar, bordeando playas y acantilados de una belleza espectacular. Una ruta senderista que sin duda, merece la pena hacer, pero no es para principiantes. El Camino de los Faros es una de las rutas de senderismo más fascinantes de Galicia, una región del noroeste de España conocida por sus paisajes dramáticos, su rica historia y su cultura vibrante. Este sendero recorre aproximadamente 200 kilómetros a lo largo de la costa de la Costa da Morte, desde Malpica hasta Finisterre, ofreciendo una experiencia única que combina naturaleza, historia, y cultura. Origen y Filosofía del Camino de los Faros Historia El Camino de los Faros fue concebido por un grupo de amigos locales en 2012, conocidos como los “trasnos” (duendes en gallego), que deseaban crear una ruta que conectara los numerosos faros de la Costa da Morte, una región famosa por sus abruptos acantilados y su mar embravecido. Estos faros han sido testigos de numerosos naufragios y son emblemáticos de la relación de Galicia con el mar. La ruta fue creada para mostrar la belleza de la costa, promover el turismo sostenible y revalorizar el patrimonio natural y cultural de la zona. Filosofía La filosofía del Camino de los Faros se centra en la idea de disfrutar y respetar la naturaleza. La ruta no solo busca atraer a los senderistas por sus paisajes espectaculares, sino también fomentar un respeto profundo por el medio ambiente y las comunidades locales. Esto incluye la conservación de la flora y fauna, la promoción de prácticas sostenibles, y el apoyo a la economía local. Recorrido y Etapas El Camino de los Faros se divide en 8 etapas, cada una con sus propias características únicas. A continuación, se describe cada etapa en detalle: 1. Malpica - Niñóns (21 km): La ruta comienza en Malpica, un pintoresco puerto pesquero. El sendero se adentra en un paisaje costero accidentado, con vistas espectaculares del Atlántico y los acantilados de la Costa da Morte. Destacan la Playa de Seaia y la Punta Nariga, con su moderno faro. 2. Niñóns - Ponteceso (27 km): Esta etapa atraviesa playas salvajes como la Playa de Niñóns y la Playa de Barda. Se pasa por los acantilados de Roncudo, famosos por sus percebes, y se llega a Ponteceso, tierra del poeta Eduardo Pondal. 3. Ponteceso - Laxe (25 km): El camino sigue el curso del río Anllóns, hasta llegar a la desembocadura en la Ría de Corme y Laxe. La Playa de Laxe y su encantador pueblo marinero son los puntos culminantes de esta etapa. 4. Laxe - Arou (17 km): Desde Laxe, la ruta pasa por la Playa de Soesto y sube hasta el Monte Castelo de Lourido, ofreciendo vistas impresionantes de la costa. El final de la etapa se encuentra en el pequeño pueblo de Arou. 5. Arou - Camariñas (23 km): Esta etapa es conocida por sus paisajes abruptos y el Faro Vilán, uno de los más emblemáticos de Galicia. Se camina por playas solitarias y se llega a Camariñas, famosa por su encaje de bolillos. 6. Camariñas - Muxía (32 km): Esta es una de las etapas más largas y exigentes. Se pasa por el Santuario de la Virgen de la Barca en Muxía, un lugar de peregrinación con vistas espectaculares del mar. 7. Muxía - Nemiña (24 km): La ruta sigue la costa hacia el sur, pasando por la Playa de Lourido y el Faro de Touriñán, el punto más occidental de la España peninsular. La etapa termina en la tranquila playa de Nemiña. 8. Nemiña - Finisterre (26 km): La última etapa lleva a los caminantes hasta el Cabo Finisterre, conocido en la antigüedad como el “fin del mundo”. El faro de Finisterre ofrece una vista impresionante y es un lugar de reflexión y celebración para los caminantes. Aspectos Destacados y Atractivos Paisaje y Naturaleza El Camino de los Faros ofrece un acceso incomparable a la belleza natural de la Costa da Morte. Los senderistas pueden disfrutar de playas vírgenes, acantilados dramáticos, bosques de pinos y eucaliptos, y formaciones rocosas únicas. La biodiversidad es rica, con numerosas especies de aves marinas y una flora variada que incluye plantas endémicas de la región. Faros Cada faro a lo largo del camino tiene su propia historia y características únicas. El Faro de Punta Nariga, con su diseño moderno, contrasta con el Faro Vilán, que tiene una historia trágica vinculada a naufragios. Estos faros no solo sirven como puntos de referencia, sino también como símbolos de la conexión de Galicia con el mar. Cultura y Patrimonio La ruta pasa por numerosos pueblos pesqueros, cada uno con su propio carácter y tradiciones. Los caminantes pueden explorar la cultura local a través de su gastronomía, festividades, y artesanía, como el encaje de bolillos en Camariñas. Además, sitios históricos como el Santuario de la Virgen de la Barca en Muxía y la historia del Cabo Finisterre añaden una dimensión cultural profunda a la experiencia. Logística y Consejos Mejor Época para Caminar El Camino de los Faros se puede realizar en cualquier época del año, aunque la primavera y el otoño son ideales debido a las temperaturas moderadas y la menor afluencia de turistas. El verano ofrece más horas de luz, pero puede ser más concurrido y caluroso. Equipamiento Es esencial llevar ropa y calzado adecuados para senderismo, protector solar, agua y comida. También se recomienda un mapa detallado de la ruta y un teléfono móvil con suficiente batería, ya que algunas áreas pueden ser remotas. Alojamiento A lo largo del Camino de los Faros, hay una variedad de opciones de alojamiento que incluyen albergues, pensiones, y casas rurales. Es aconsejable reservar con antelación, especialmente en temporada alta. Seguridad Los senderistas deben estar preparados para cambios climáticos repentinos y condiciones costeras variables. Se recomienda caminar en grupo o informar a alguien de la ruta planeada. También es importante respetar las señales y advertencias locales. Conclusión El Camino de los Faros es una joya del senderismo en Galicia, ofreciendo una mezcla única de belleza natural, patrimonio cultural y desafío físico. A través de sus etapas, los caminantes pueden experimentar la costa salvaje de la Costa da Morte, descubrir la historia de sus faros y sumergirse en la cultura local. Es un camino que invita a la reflexión, la aventura, y el descubrimiento de uno de los paisajes más impresionantes de España. Puedes leer más y comentar en mi web, en el enlace directo: https://luisbermejo.com/fragmentos-zz-podcast-05x48/ Puedes encontrarme y comentar o enviar tu mensaje o preguntar en: WhatsApp: +34 613031122 Paypal: https://paypal.me/Bermejo Bizum: +34613031122 Web: https://luisbermejo.com Facebook: https://www.facebook.com/ZZPodcast/ X (twitters): https://x.com/LuisBermejo y https://x.com/zz_podcast Instagrams: https://www.instagram.com/luisbermejo/ y https://www.instagram.com/zz_podcast/ Canal Telegram: https://t.me/ZZ_Podcast Canal WhatsApp: https://whatsapp.com/channel/0029Va89ttE6buMPHIIure1H Grupo Signal: https://signal.group/#CjQKIHTVyCK430A0dRu_O55cdjRQzmE1qIk36tCdsHHXgYveEhCuPeJhP3PoAqEpKurq_mAc Grupo Whatsapp: https://chat.whatsapp.com/FQadHkgRn00BzSbZzhNviThttps://chat.whatsapp.com/BNHYlv0p0XX7K4YOrOLei0

The Biomedical Advanced Research and Development Authority (BARDA) helped bring Moderna's mRNA vaccine through clinical trials to market. BARDA's Division of Research, Innovation, and Ventures (DRIVe) is its in-house biotech venture capital firm, charged with identifying and incubating technologies for U.S. biodefense and preparedness.Today's interviewee is Dr. Sandeep Patel, the Director of DRIVe from March 2020 to March 2024. Patel helped architect the program's VC-inspired model and led the organization through its COVID response. We covered:(00:00) Introduction(00:20) How cost-effective is BARDA?(09:38) Venture-capitalism in government(26:14) Hiring talent(34:35) Question grab-bag This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.statecraft.pub

IMSS aplica prueba de detección de hepatitis C Encarcelan a la presidenta municipal de San Juan Cuicatlán, Oaxaca  Biden debe reconsiderar seriamente el futuro de su candidatura: Barak ObamaMás información en nuestro podcast

Please remember to rate and review our podcast! Check out your YouTube channel @comadresycomics CHISME DE LA SEMANA: Anger over the use of AI in art heated up over the weekend after Adi Granov called out DC cover artist Francesco Mattina for using AI in a variant cover for Superman #18. ON MY RADAR: House of the Dragon on HBO season 2 & DC's newest YA graphic novel, Barda. HORA DE LA CERVECITA:  Tropicália by Creature Comforts BOOK REVIEW: Doña Quixote: Rise of the Knight by Rey Terciero (Author), Monica M. Magaña (Illustrator) EN LA LIBRERIA: Divine Intervention: A Chaotic Queer Fantasy Rom-Com-To get the promotion of their dreams, a mischievous earth-bound angel must get two ex-best friends to admit their love to each other. http://kck.st/45HvVvz JUNTOS Y FUERTES: The aim of Little Fish classes is to educate students using the standards of a traditional art school and the comic book industry with the passion and the openness of a relaxed studio environment www.lilfish.us   @littlefishcomicbooks SALUDOS: Kristian Horn @periwinklepuss www.periwinklepuss.com Follow us on socials @comadresycomics Visit our website comadresycomics.com

Reviews: Free Comic Book Day 2024 - Absolute Power, Barda, Barkham Asylum, Blood Hunt/X-Men, Dark Horse, Doctor Who, Gannibal, MAD Magazine, Marvel's Voices, Star Wars, Teenage Mutant Ninja Turtles, Ultimate Universe/Spider-Man.  Yes, we know. We're a over a month late for Free Comic Book Day comics. Apologies for that but we're here now with lots of reviews! Big focus on DC and Marvel Comics w/ a few others thrown in the mix. A lot of great teasers leading into series or graphic novels and even a fun reprint. We'll def be picking up some of the books these lead into.   Also, get a hold of us! Thanks for listening!

The avian flu outbreak is a fire drill that is showing how poorly the U.S. is prepared for the next pandemic. On the latest BioCentury This Week podcast, BioCentury's editors recap last week's BioCentury Show conversation with Rick Bright, including the former BARDA director's insights on the opportunities for biotechs to help fill voids in surveillance, point-of-care diagnostics, vaccines and therapeutics and the need for the government to provide leadership and funding to empower industry. They also discuss new SEC rules that will make reverse mergers less attractive; the Supreme Court's mifepristone ruling and a trio of neuro-focused stories -- one on FDA's guidance on presymptomatic Alzheimer's, another on an advisory committee's discussion about Eli Lilly's anti-amyloid therapy donanemab and a third focused on what neuroscience biotech companies need to consider when pitching VCs and pharmas. This week's podcast is sponsored by Nxera Pharma.0:01 - Sponsor Message: Nxera Pharma01:40 - Pandemic Prep Problems11:11 - Reverse Mergers15:43 - Alzheimer's25:31 - SCOTUS

Today we talk about Anthony Ivo, who is obsessed with immortality but probably most notable for his creation of the Amazo robot which can absorb and use super powers. Today's mentioned & relevant media: -The Brave and the Bold (1955) #30 -The Flash (1959) #158 -Action Comics (1938) #480-483 -Justice League of America (1960) #218, 258-261 -Justice League Quarterly (1990) #5 -JLA (1996) #5, 83 -Hourman (1999) #1-2 -Justice League of America (2006) #2-7, 25 -JLA: Classified (2004) #38-39, 41, 44 -Salvation Run (2007) #3 -Justice Leage: Generation Lost (2010) #11, 15, 17-19, 22-23 -Power Girl (2009) #19-20 -Supergirl (2005) #65-67 -Justice League (2011) #3, 6, 23, 23.4: Secret Society -Justice League of America (2013) #1-2, 4-5 -Justice League (2018) #13, 27 -WILDC.A.T.S (2022) #2 -Batman/Superman: World's Finest (2022) #14-15 -Star Trek: Celebrations -DC Pride 2024 -Barda by Ngozi Ukazu -X-Men: The Wedding Special (2024) #1 -The Boy Wonder (2024) #2 Thanks to Victoria Watkins for our icon! Support Capes and Japes by: Checking out our Patreon or donating to the Tip jar Find out more on the Capes and Japes website.

Today on The Prather Point LIVE at 2 pm ET / 11 am PT on RUMBLEhttps://rumble.com/v4zk2le-breaking-barda-briefs-next-bioweapon-at-bio-con.htmlMIDWAY - REAL INTEL REPLACED WITH 82 YEARS OF FAKE FAILURES!FAUCI BRIBED SCRIPPS SCIENTIST TO CALL ENGINEERED VIRUS CONSPIRACY THEORY! H5N1 = FALSE FLAG, MALAYSIAN FLU STRAIN = PLAN, & BARDA'S GOT FILLED SYRINGES!MD DR. EBEN ALEXANDER'S 7 DAY COMA, NEAR DEATH EXPERIENCE, & DIVINE ENCOUNTERS!

Jace chats with New York Times best-selling cartoonist Ngozi Ukazu about her upcoming Young Adult graphic novel BARDA. Ngozi is a self-professed life-long DC Comics fan, so it was a dream come true for her to writer and illustrate this story. Taking inspiration from the legendary Jack Kirby, Ngozi weaves a wonderful Fourth World tale starring Big Barda as she begins to question the motivations of Apocalypse and meets Scott Free for the first time. Ngozi talks about her inspirations, the fun in writing the Female Furies and so much more. Be sure to listen in and pick up the graphic novel when it drops June 4th.

FCBD Releases: Barkham Asylum, Barda, Absolute Power, Energon Universe Superman: House of Brainiac Special Blood Hunt #1 Space Ghost #1 Get Fury #1

Welcome to Comics From The Multiverse, our DC comics podcast! Discussed this week: 0:00:00 - Intro 0:12:03 - Comixology Top 10 0:21:10 - News 0:23:22 - Batman #146 (LGY #911) (Chip Zdarsky and Jorge Jimenez) 0:55:31 - Birds of Prey #8 (LGY #206) (Kelly Thompson and Javier Pina & David Lopez) 1:07:02 - Shazam #10 (Josie Campbell and Emanuela Lupacchino & Mike Norton) 1:21:11 - Poison Ivy #21 (G Willow WIlson and Marcio Takara) 1:33:34 - Blue Beetle #8 (Josh Trujillo and Adrian Guitierrez) 1:40:54 - PATREON: American Vampire Second Cycle #6 1:57:32 - Best art, cover and books of the week. patreon: https://www.patreon.com/mildfuzztv twitter: @DCComicsPodcast discord: https://discord.gg/8fbyCehMTy Audio: https://comicsfromthemultiverse.podbean.com/ Other Links: https://linktr.ee/mildfuzz

Episode 720 :  Green Arrow 9 and Birds of Prey 7: Sean and Jim jump back to some books that they haven't discussed in awhile with a focus on Oliver Queen and family in Green Arrow with an issue that has ramifications from Beast World. The guys also take a look at the new arc of Birds of Prey with the official return of an old favorite to the team. We are on Threads! https://www.threads.net/@ragingbulletspodcast Sean is a cohost on “Is it Jaws?” Check it out here : https://twotruefreaks.com/podcast/qt-series/is-it-jaws-movie-reviews/ Upcoming: Nightwing/Titans Final March Release : 18 Years of Podcasting Celebration : We are joined by longtime friend of the show Mike Gordon to discuss the first trade of Justice League International covering issues 1-7 from Giffen, DeMatteis, and Maguire. Contact Info (Social Media and Gaming) Updated 9/23: https://ragingbullets.com/about/ Facebook Group: https://www.facebook.com/groups/401332833597062/ Show Notes: 0:00 Show opening, http://www.heroinitiative.org, http://cbldf.org/,http://www.DCBService.com, http://www.Instocktrades.com, show voicemail line 1-440-388-4434 or drnorge on Skype, and more.   2:27 Birds of Prey 33:50 Green Arrow 56:50 Closing We'll be back in a week with more content.  Check our website, Twitter and our Facebook group for regular updates.

In today's episode of Med Tech Gurus, we have Mr. Wensheng Fan CEO of SpectralAI. We get into a wide-ranging conversation including how the SpectralAI team achieve a BARDA grant. We also get into how SpectralAI managed a SPAC strategy to go public. Wensheng did not stop there. We got into how SpectralAI has managed a series of pivotal studies to demonstrate their effectiveness and outcomes. Then why data integrity and quality is such an important factor for these studies and for product performance.  This is a fun and informative episode!

The Tom Renz Show – Project NextGen is (again) being run as a "national security project (DOD project with BARDA and BioDefense are all over this), so there will be zero transparency. What we do know is they are working on vaccines that can impact you if you breathe them and also vaccines that are based on saRNA (self-amplifying RNA). These lab-created RNA particles get into your system and self-replicate forever...

The Tom Renz Show – Project NextGen is (again) being run as a "national security project (DOD project with BARDA and BioDefense are all over this), so there will be zero transparency. What we do know is they are working on vaccines that can impact you if you breathe them and also vaccines that are based on saRNA (self-amplifying RNA). These lab-created RNA particles get into your system and self-replicate forever...

Jim Collins is one of the leading biomedical engineers in the world. He's been elected to all 3 National Academies (Engineering, Science, and Medicine) and is one of the founders of the field of synthetic biology. In this conversation, we reviewed the seminal discoveries that he and his colleagues are making at the Antibiotics-AI Project at MIT.Recorded 5 February 2024, transcript below with audio links and external links to recent publicationsEric Topol (00:05):Hello, it's Eric Topol with Ground Truths, and I have got an extraordinary guest with me today, Jim Collins, who's the Termeer Professor of Medical Engineering at MIT. He also holds appointments at the Wyss Institute and the Broad Institute. He is a biomedical engineer who's been making exceptional contributions and has been on a tear lately, especially in the work of discovery of very promising, exciting developments in antibiotics. So welcome, Jim.Jim Collins (00:42):Eric, thanks for having me on the podcast.Eric Topol (00:44):Well, this was a shock when I saw your paper in Nature in December about a new structure class of antibiotics, the one from 1962 to 2000. It took 38 years, and then there was another one that took 24 years yours, the structural antibiotics. Before I get to that though, I want to go back just a few years to the work you did published in Cell with halicin, and can you tell us about this? Because when I started to realize what you've been doing, what you've been chipping away here, this was a drug you found, halicin, as I can try to understand, it works against tuberculosis, c. difficile, enterobacter that are resistant, acinetobacter that are resistant. I mean, this is, and this is of course in mice models. Can you tell us how did you make that discovery before we get into I guess what's called the Audacious Project?Jim Collins (01:48):Yeah, sure. It's actually a fun story, so it is origins go broadly to institute wide event at MIT, so MIT in 2018 launched a major campus-wide effort focused on artificial intelligence. The institute, which had played a major role in the first wave of AI in the 1950s, 1960s, and a major wave in the second wave in the 1980s found itself kind of at the wheel in this third wave involving big data and deep learning and looked to correct that and to correct it the institute had a symposium and I had the opportunity to sit next to Regina Barzilay, one of our faculty here at MIT who specializes in AI and particularly AI applied to biomedicine and we really hit it off and realized we had interest in applying AI to drug discovery. My lab had focused on antibiotics to then close to 15 years, but primarily we're using machine learning and network biology to understand the mechanism of action of antibiotics and how resistance arise with the goal of boosting what we already had, with Regina we saw there was an opportunity to see if we could use deep learning to get after discovery.(02:55):And notably, as you kind of alluded in your introduction, there's really been a discovery void and the golden age of discovery antibiotics was in the forties, fifties and sixties before I was born and before you had the genomic revolution, the biotech revolution, AI revolution. Anyways, we got together with our two groups, and it was an unfunded project and we kind of cobbled together very small training set of 2,500 compounds that included 1,700 FDA approved drugs and 800 natural compounds. In 2018, 2019, when you started this, if you asked any AI expert should you initiate that study, they would say absolutely not, there's going to be two big data. The idea of these models are very data hungry. You need a million pictures of a dog, a million pictures of a cat to train a model to differentiate between the cat and the dog, but we ignored the naysayers and said, okay, let's see what we can do.(03:41):And we apply these to E. coli, so a model pathogen that's used in labs but is also underlies urinary tract infections. So it's a look to see which of the molecules inhibited growth of the bacteria as evidence for antibacterial activity and we could have measured and we quantified each of their effects, but because we had so few compounds, we just discretized instead, if you inhibited at least 80% of the growth you were antibacterial, and if you didn't achieve that, you weren't antibacterial zero in ones. We then took the structure of each molecule and trained a deep learning model, specifically a graphical neural net that could look at those structures, bond by bond, substructure by substructure associated with whatever features you look to train with. In our case, making for good antibiotic, not for good antibiotic. We then took the train model and applied it to a drug repurposing hub as part of the Broad Institute that consists of 6,100 molecules in various stages of development as a new drug.(04:40):And we asked the model to identify molecules that can make for a good antibiotic but didn't look like existing antibiotics. So part of the discovery void has been linked to this rediscovery issue we have where we just keep discovering quinolones like Cipro or beta-lactams like penicillin. Well, anyways, from those criteria as well as a small tox model, only one molecule came out of that, and that was this molecule we called halicin, which was named after HAL, the killing AI computer system from 2001 Space Odyssey. In this case, we don't want it to kill humans, we want it to kill bacteria and as you alluded, it turned out to be a remarkably potent novel antibiotic that killed off multi-drug resistant extensively drugs, a pan-resistant bacteria went after to infections. It was affected against TB, it was affected against C. diff and acinetobacter baumannii and acted to a completely new mechanism of action.(05:33):And so we were very excited to see how AI could open up possibilities and enable one to explore chemical spaces in new and different ways. We took them model, then applied it to a very large chemical library of 1.5 billion molecules, looked at a subset of about 110 million that would be impossible for any grad student, any lab really to look at that experimentally but we looked at it in a model computer system and in three days could screen those 110 million molecules and identified several new additional candidates, one which we call salicin, which is the cousin of halicin that similes broad spectrum and acts to a novel mechanism of action.Eric Topol (06:07):So before we go further with this initial burst of discovery, for those who are not used to deep neural networks, I think most now are used to the convolutional neural network for images, but what you use specifically here as you alluded to, were graph neural networks that you could actually study the binding properties. Can you just elaborate a little bit more about these GNN so that people know this is one of the tools that you used?Jim Collins (06:40):Yeah, so in this case, the underlying structure of the model can actually represent and capture a graphical structure of a molecule or it might be of a network so that the underlying structure itself of the model will also look at things like a carbon atom connects to an oxygen atom. The oxygen atom connects to a nitrogen atom and so when you think back to the chemical structures we learned in high school, maybe we learned in college, if we took chemistry class in college, it was actually a model that can capture the chemical structure representation and begin to look at sub aspects of it, associating different properties of it. In this case, again, ours was antibacterial, but it could be toxic, whether it's toxic against a human cell and the model, the train model, the graph neural model can now look at new structures that you input them and then make calculations on those bonds so a bond would be a connection between two atoms or substructures, be multiple bonds, interconnecting multiple atoms and assign it a score. Does it make, for example, in our case, for a good antibiotic.Eric Topol (07:48):Right. Now, what's also striking as you set up this collaboration that's interdisciplinary with Regina, who I know of her work through breast cancer AI and not through drug discovery and so this was, I think that new effort and this discovery led to this, I love the name of it, Audacious Project, right?Jim Collins (08:13):Right. Yeah, so a few points on the collaboration then I'll speak to Audacious Project. In addition to Regina, we also brought in Tommi Jaakkola, another AI faculty member and marvelous colleague here at MIT and really we've benefited from having outstanding young folks who were multilingual. We had very rich, deep trained grad students from ML on Regina and Tommi's side who appreciated the biology and we had very richly, deeply trained postdocs, Jon Stokes in particular from the microbiology side on my side, who could appreciate the machine learning and so they could speak across the divide. And so, as I look out in the next few decades in this exciting time of AI coming into biomedicine, I think the groups will make a difference of those that have these multilingual young trainees and two who are well set up to also inject human intelligence with machine intelligence.(09:04):Brings the Audacious Project. Now, prior to our publication of halicin, I was invited by the Audacious Project to submit a proposal, the Audacious Project is a new philanthropic effort run by TED, so the group that does the TED Talks that's run by Chris Anderson, so Chris had the idea that there was a need to bring together philanthropists around the world to go for a larger scale in a collective manner toward audacious projects. I pitched them on the idea that we could use AI to address the antibiotic resistance crisis. As you can appreciate, and many of your listeners can appreciate that we're doomed if we don't actually address this soon, in that the number of resistance strains that are in our communities, in our hospitals has been growing decade upon decade, and yet the number of new antibiotics being developed and approved has been dropping decade upon decade largely because the antibiotic market is broken, it costs just as much to develop an antibiotic as it does a cancer drug or a blood pressure drug.(09:58):But antibiotic you take once or maybe over the course of three to five days, blood pressure, drug cancer drug you might take for months if not for the rest of your life. Pricing points for antibiotics are small dollars, cancer drugs, blood pressure drugs, thousands if not hundreds of thousands. We pitched this idea that we can maybe turn to AI and use the power of AI to address this crisis and see if we could use our wits to outcompete the genes of superbugs and Chris and his team really were taken with this, and we worked with them over the course of nine months and learned how to make the presentations and pulled this together. Chris took our pitches to a number of really active and fantastic philanthropists, and they got behind us and gave us a good amount of money to launch what we have now called the Antibiotics-AI Project at MIT and in conjunction with it and also using funding from the Audacious Project, we've launched a nonprofit called Phare Bio which is French for lighthouse, so our notion is that antibiotics are public good that we need to get behind his community and Phare Bio, which is run by Akhila Kosaraju, she's the CEO and President, is the mission of which is to take the most promising molecules out of the antibiotics AI project and advance them towards the clinic through partnerships with biotech, with pharma, with other nonprofits, with nation states as needed.Eric Topol (11:18):Well, before I get to the next chain of discovery and as explain ability features, which we all like to see when you can explain stuff with AI, did halicin because of this remarkable finding, did it get into clinical trials yet?Jim Collins (11:36):It's being advanced quite nicely and aggressively by Phare Bio. So Phare Bio is in discussions with the Department of Defense and BARDA, and actually on an interesting feature of halicin is that it acts like a flash bomb in the gut, meaning that when delivered orally to the gut, it only acts briefly and very quickly in a fairly narrow spectrum manner as well, so that it can go after pathogens sparing the commensals. One of the challenges our US military face is one of the challenges many militaries face are gut issues when soldiers are first deployed to a new location, and it can disable the soldiers for three to four weeks. And so, there's a lot of excitement that halicin might be effective as a treatment to help prevent gut dysbiosis resulting from new deployments.Eric Topol (12:27):Oh wow. That's another application that I would never have thought of. Interesting, so you then moved on to this really big report in Nature, which I think this is now involving a transformer model as I recall. So you can explain the difference and you made a discovery from a massive, again, number of potential compounds to staph aureus resistant methicillin resistant agents that were very potent in vivo. So how did you make this big jump? This is a whole new structural class of antibiotics.Jim Collins (13:11):Yeah, so we made this jump, this was an effort led by Felix Wong, who's a really talented postdoc in my lab, and we got intrigued of to what extent could we expand the utility of AI and biology of medicine. As you can appreciate that, that many of our colleagues are underwhelmed by the black box nature of many AI models and by black box I mean that when you train your model, you then largely use it as a filter where you'll provide the model with some input. You look at the output and the outputs, what's of interest to you, but you don't really understand in most cases, what guided the model to make the prediction of the output that you look at and that can be very unsatisfactory for biology, interested in mechanism. It can be very unsatisfactory for physicians interested in understanding the underlying disease mechanism.(13:57):It can be unsatisfactory for biotech and drug discoveries that want to understand how drugs act and what maybe underlies meaningful structural features. So with Felix, we decided it'd be interesting if you could open up the box. So could you look inside the model to see what was being learned? We are able to open up, in this case actually, we primarily focused on graph neural nets. We now have a new piece we're just about to submit on transformers, but in this case, we could open up and look to see what were the rationales, what were the chemical substructures that the model was pointing to in each compound that was leading to the high prediction that it could make for a good antibiotic and these rationales we then used as hooks, I should notably say, that we were able to identify the rationales from these large collections using algorithms that would develop by DeepMind as part of their AlphaGo program.(14:51):So AlphaGo was developed by DeepMind as a deep learning platform to play and win go the ancient Asian board game and we used similar approaches called Monte Carlo Tree Search that allowed us to identify these rationales that we effectively then used as hooks and kind of organizing hooks on screens where you can envision or appreciate that most exposed screens give you one-offs. This molecule does what you want and silico screens are similarly designed with these rationales. We could use them as organizing hooks to say, ah, these compounds that are identified as making for very good antibiotics all have the same substructure and thus they likely in the same class and act in similar mechanism and this led us to identify five novel classes, one of which we highlighted in this piece that acts very effectively against MRSA, so methicillin-resistant staph aureus you alluded, which is probably the most famous of the antibiotic resistant pathogens that we even outside infectious are quite familiar with. It be devil's athletes, so NFL players are often hit with MRSA, whether from scraping their limbs on AstroTurf or from actually surgeries to say, for example, correct something at their knee. This new class had great efficacy in animal models, again, acting through a new mechanism.Eric Topol (16:12):Will you bring that forward like halicin through this same entity?Jim Collins (16:17):Yes. We've now provided the molecules to Phare Bio and they're digging in to see which of these might be the most exciting and interesting to advance clinically.Eric Topol (16:26):I mean, it's amazing because this area is so neglected. Maybe you can help explain, since we're talking about existential threats as we get more and more resistant antibiotics and the biopharma industry is basically not into this and it relies on the work that you've been doing perhaps or other groups, I don't know of any that are doing more than you. I mean, it's incredible to me. Is it just because of the financial aspects that there's no business in the life science industry?Jim Collins (17:03):It's an interesting challenge. So I've thought about it. I really haven't come up with a great solution yet, but I think you've got multiple factors at play. One is that I think all of us, every one of your listeners has lost someone to a bacterial infection, but in most cases you don't realize you lost them to a bacterial infection. It might be that your elderly relative went into the hospital with a condition but acquired hospital-based infection and died subsequently from that and happened quite quickly. Another cases, again, it's secondary. Notably, during the pandemic, one out of seven individuals hospitalized for Covid had a bacterial infection and 50% of those who died had a bacterial co-infection. And noted by going back to the Spanish flu of over a hundred years ago. It was as deadly as it was because we didn't have antibiotics and most of the folks that died had a bacterial co-infection.(17:56):So you have this in the backdrop, you then have that, nobody's kind of gotten behind it, so we don't have any major foundation addressing antibiotic resistance. There are no charity walks, there are no charity runs, there is no month, there is no color, there are no ribbons, there are no celebrity behind it, there's just not known so it hasn't captured the public's imagination. AThen you come with that, this backdrop of the broken market where I said shared, it's really expensive to develop a new antibiotic, but if you develop a new antibiotic, the tendency now will be to shelve it until it's desperate so now even the young companies that had developed and gotten an antibiotic through to approval often went bankrupt because the model, the market couldn't provide them with revenue to go after the next one or sustain their efforts. And so you have pharma biotech jumping out. I think we need two-pronged effort going forward. I do think we need nation states to come forward and get behind this, and I think we increasingly need philanthropists to come forward and go after it. As I share your term of existential threat, I think if you speak with most educated individuals, antibiotic resistance broadly, antimicrobial resistance will be on everyone's existential threat list but notably of that list, it's the cheapest one that can be solved.Eric Topol (19:09):Well, you're showing that you've got the most extraordinary candidates that have been found in decades. So that says a lot right there.Jim Collins (19:18):Important step, yeah. So I think we've got additional innovation needed in the models to address this, and until we have that address, then this interesting discoveries we and others are making will not get to patients. So we need to have that additional next step to close this gap.Eric Topol (19:32):Now, obviously this has relied on AI and the progress that's occurring in AI to enable some of your work. I am fascinated by the use of AlphaGo. Most times we hear about using AlphaFold2, but you actually use AlphaGo the original game DeepMind work but there also was the progress of from deep neural networks to transformer models and your ability now to basically exemplify what can be achieved in drug discovery using the progress in multimodal AI. Is this something that is making a difference for you and your group?Jim Collins (20:13):It is, it's huge. I think it's very early in terms of the introduction to these new tools extensively within drug discovery. Machine learning has been used for over two decades, both supervised learning and unsupervised learning. Now we're seeing groups coming in for the deep learning efforts. It's largely data-driven so in fact, with the exception of sequences, most of drug discoveries not yet big data in the big data phase, but it's beginning to change. It's truly been transformative for us, so we've used graph neural nets primarily for our discovery efforts. We're now beginning to incorporate language models as multimodal models along with the graph neural nets as well as to see to what extent pre-trained language models. For example, mobile form from IBM, which was trained on PubChem and the ZINC database could be fine-tuned with small amounts of training data, screening data from a resistant organism.(21:06):Third, and I made an indirect allusion already, we've been looking at using transformers and genetic algorithms in older form of AI tech for design of novel antibiotics so we've been now looking to see using fragments as a starting base, using trained models to build out novel antibiotics that can then be de novo designed. One of the big challenges in that space is how do you synthesize these molecules? So you have both the challenge of can you come up with a small number of steps that enable you to synthesize? And second is could you find somebody to synthesize them? And each of those remains very big challenges. My faculty colleague here at MIT, Connor Coley's probably one of the world leaders, easily, he's in using AI to calculate the synthesized ability of a molecule, but we still have gaps in that we don't have the community resources to make most of what we come up with.Eric Topol (21:58):Well, one of the features of large language models that David Baker at the Protein Design Institute exploited is its ability to hallucinate and come up with proteins that don't exist. Can you do the same thing in your design of antibiotic candidate molecules in a way that is not worrying about the synthesis, but just basically the hallucinatory behavior of large language models?Jim Collins (22:28):It's interesting, so yes and so David's work is marvelous and we're big fans and longtime friends of his work. Yes, so we've been driving these models truly to do de novo synthesis. So based on what has been learned, can you put together molecules that one's never seen before? We're doing it quite successfully. It becomes interesting from the hallucination in that it comes out really more of these models making stuff up and ours it's really more directing the hallucinations, right? Really looking to see can we harness the imagination of the models in order to move them forward in very creative design manners.Eric Topol (23:08):Yeah, I mean, I think most people have a negative connotation of hallucinations, but these are the smart variety potentially. This in many ways you could say there's so much crowded interest in the drug discovery AI world, but what you're doing now seems to be setting the pace in many respects for others to follow such remarkable advances in a short time. By the way, we'll link to that TED talk you gave in April 2020, where in seven minutes you went over what you're doing of course and who would've, and that was in 2020 that where you'd be three or four years later, and that was what you're going to do over the next seven years with seven new classes of new antibiotics. Now, before we wrap up, it isn't just that you're an AI antibiotic, you and your team antibiotic discover and doing compressing in time, what has taken decades that you're doing in months, but also you are a father of figure in the field of synthetic biology and I wonder if you, before we wrap up, can explain not only what synthetic biology is since a lot of people don't really know what that means, but how does that dovetail with your efforts in what we've been discussing?Jim Collins (24:33):Yeah, thanks. So synthetic biology is a relatively new field that's bringing together engineers with biologists to use engineering principles to model design and build synthetic gene networks and other molecular components that can be used to rewire and reprogram living cells and cell-free systems, endowing them with novel functions of a variety of applications. So the circuits, these programmable cells are impacting broad swats of the economy from food and water to health and sustainability of bioenergy to human health. Our focus is primarily human health and we've been advancing the idea that you can reprogram bacteria to detect and treat bacterial infections. So we've shown you can use this to go after cholera, we've shown you can use is to prevent antibiotic induced gut dysbiosis. We've also used synthetic biology to create whole new classes of diagnostics. For example, paper-based ones using RNA sensors for Ebola, for Zika and for Covid.(25:33):How it dovetails with what we talked about is that I think there's a great opportunity now to turn to AI to expand synthetic biology, both expanding the number of parts we have to re-engineer living systems as well as to better infer design principles that can be used to reprogram rewire living systems. We're beginning to advance, we're not yet at the SynBio AI project phase, but very early efforts and David's dominating the protein space and we and others are beginning to now movement to the RNA space. So to what extent can we create large libraries of RNA components, train language-based models, structure-based models that can both predict RNA structure more critically predict RNA function and as you know from your marvelous work and what's happening is that it's the exciting age of RNA of getting after RNA therapeutics, be it mRNA or CRISPR related and we still need to get better at our ability to design those therapeutics with certain functions in mind, and we think AI is going to help get us there faster.Eric Topol (26:34):Well, speaking of that, there was a paper this week in Cell by McCafferty and colleagues, and one of the sentences that struck me, we are standing on the cusp of a new era of biology, where the integration of multimodal structural datasets with multiscale physics-based simulation will enable the development of visible, virtual cells. This is yet another lineage or direction of where we're headed with AI, but this fusion of the advances that are occurring right now in biology with AI that extend in many different directions, it's so exciting and you are basically nailing it. I mean, you're putting points on the board, Jim, and I just have to say, I'm blown away by what you've been accomplishing in a time space that's so incredibly compressed.Jim Collins (27:40):Oh, well thanks. Well, you think back to the early days of molecular biology and physicists like Francis Crick and Max Delbrück played huge pioneering roles and then in the second wave in the eighties or so, you had other physicists like Walter Gilbert playing big roles. I do think physicists computer scientists are starting now to play big roles in this next phase where we need tools like AI in order to really grapple with and harness the complexity, both the biology and the chemistry that underlies living cells. They can kind of expand our intuitions both to understand and to really control these systems for good going forward.Eric Topol (28:15):Well, you're doing it and we're be cheering for the success of these drugs that you've come up with in the clinical trials as they go forward because they look so remarkably promising. You even highlighted ways that I wouldn't have envisioned where they could make a difference, so we'll follow your work, you and your colleagues with great interest. Thanks so much for joining,Jim Collins (28:37):Eric, thanks for having me. Enjoyed our conversation.******************************************************************************Thanks for listening to Ground Truths. Please share if you found this podcast informative.Full video interview will post here Get full access to Ground Truths at erictopol.substack.com/subscribe

Rivanna Medical is a Virginia-based developer of ultrasound imaging technologies. Accuro, the company's first product, is a “stud finder for the spine” for more accurate needle placement during spinal and epidural procedures.In Episode #29, Andy Rogers of Key Tech talks with Rivanna's Chairman, CEO, and Co-founder, Will Mauldin, Ph.D., about the role of data in his company's AI-powered product. Need to know Three million vaginal and caesarian births in the United States require anesthesia injected into the epidural space around the spinal cord. Twenty million patients receive epidurals during surgery or as part of a treatment program for chronic pain. However, there are complications. For example, post-dural-puncture headaches occur when a needle punctures the dura and fluid leaks from the spinal canal. First-attempt success rates are around forty percent in challenging populations, such as obese patients or those with spinal abnormalities.  Success rates with Rivanna's Accuro ultrasound imager approach seventy-five percent. The nitty-grittyAlthough physicians have used general-purpose ultrasound imagers to scout needle placement, most anesthesia providers don't have the skills to make it common practice. By focusing on one indication, distinguishing epidural tissue from bone, Rivanna designed a simple handheld device that uses AI-powered software to streamline needle placement.Accuro's small size and integrated screen make identifying and marking the needle insertion site easier. In addition, the device's transducers interact with bony tissue better than general-purpose devices designed to image soft tissue.A focused value proposition also lets Rivanna use neural network algorithms to automate the identification of bone and epidural tissue and guide needle placement more accurately.Data that made the difference:Conversations with obstetrics anesthesia providers let Mauldin identify the value proposition. “It became pretty clear from those qualitative market research interviews,” Mauldin says, “that the problem is just where do I place the needle to begin with and on what trajectory?”Rivanna launched Accuro in 2015, but medical societies like the American Society of Anesthesiologists need more data to recommend ultrasound image-guided epidural procedures. Mauldin explains that Accuro's next iteration requires identifying “what kind of endpoints would move society guidelines to point to an image-guided standard of care? What clinical evidence do we need to support in order to allow the societies to make that determination?”A new product line required gathering even more data. Today, seven percent of emergency department (ED) patients have suspected wrist or ankle fractures. The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) is concerned that terrorist attacks could overwhelm EDs with hundreds of fracture patients. Rivanna received BARDA funding to design a portable ultrasound bone tissue imager.“We made it through the base segment,” Mauldin explains. “That was about gathering data. We interacted with 180 different emergency physicians, emergency department directors, orthopedists, and radiologists to answer the question: is there a market here for the indication of bone fracture bedside assessment? Fortunately, the answer was yes.” 

When it comes to landing and executing strategic partnerships, Regeneron puts on a clinic. Partnerships, acquisitions, licensing agreements, and other deals large and small with Intellia, Decibel Therapeutics, BARDA, Alnylam, and Sonoma Therapeutics are just a sampling of those making news this year alone. The man behind much of that dealmaking is none other than Nouhad Husseini, SVP and Head of Business Development and Corporate Strategy at Regeneron. He's a guy who's deftly married the art and science of biopharma dealmaking, and on this episode of the Business of Biotech podcast, we're getting introspective with this legend in the making, who our friend Allan Shaw says “turns the deals he touches into gold.” Strategic dealmaking is central to the biotech business, and today's episode offers a master class. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!